{"prompt": "['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', 'Note: fibromyalgia is acceptable.', 'Exclusion Criteria #10: Subjects with medical', 'Clarification of who is', 'conditions other than those identified in', 'restricted from taking', 'Exclusion Criteria 7 who are currently Currently', 'specified medications', 'receiving or has received oral, inhaled, or parenteral', 'corticosteroids, immunosuppressive agents', 'Synopsis: Exclusion', 'Exclusion Criteria #11: Clinical laboratory values', 'Plasma total protein', 'Criteria;', 'that may impair wound healing; for example, plasma', 'restriction removed. This is', 'total protein<<-g/dL, hemoglobin <10 g/dL, or', 'not an accurate stand alone', 'HbAlc>12%', 'indicator of wound healing.', 'Section 7.2: Exclusion', 'Criteria', 'Exclusion Criteria #18: Severe secondary', 'Clarification on the type of', 'lymphedema as diagnosed by clinical findings in', 'lymphedema to be excluded.', 'inferior members (e.g., legs)', 'Section 7.3:', 'Patient is administered any of the following', 'To be consistent with', 'Withdrawal, Removal,', 'prohibited therapies after enrollment into the', 'changes to Exclusion #7 and', 'and Replacement of', 'study:-any-antibiotic therapy; oral, inhaled, or', 'Exclusion #10', 'Patients', 'parenteral corticosteroids, immunosuppressive', 'agents, or cytotoxic agents (see Exclusion Criteria', '#7 and Exclusion Criteria #10 for exceptions to', 'this exclusion); or any other investigational drug or', 'device not utilized in this study.', 'Section 8.3:', 'After accountability has been monitored for a', 'Subjects are permitted to', 'Accountability and', 'completed or withdrawn patient, previously', 'keep previously dispensed', 'Compliance of', 'dispensed study product will be either given to the', 'Prontosan upon termination', 'Treatment', 'subject, returned to the Sponsor or destroyed on-site.', 'or completion of the study.', 'Section 8.4.2: Prior', 'Oral or intravenous antibiotie therapy, Topica', 'Use of non-wound related', 'and Concomitant', 'antibiotics not applied to the wound are', 'antibiotic therapy is', 'Medications', 'acceptable. Any antibiotic therapy for', 'permitted during the study.', 'treatment of the wound. Antibiotic therapy', 'for treatment of infections not related to the', 'wound are acceptable.', 'Oral, inhaled, or parenteral corticosteroids,', 'To be consistent with', 'immunosuppressive agents, or cytotoxic agents', 'changes to Exclusion #4 and', '(see Exclusion Criteria #7 for exceptions)', 'Exclusion #7', 'At the re-screening, the patient must still', 'meet all inclusion criteria and not exhibit any', 'exclusion criteria, and the appropriate washout time', 'for antibiotics (147 days)', 'Section 10.3: Wound', 'Wounds are to be measured using the clock method', 'Site are permitted to use', 'Measurement and', 'with the standard, single-use, disposable rulers', 'their own disposable rulers.', 'Photography', 'provided by the Sponsor.', 'Appendix 2:', '14 November 2018', 'Page 6']['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', 'Amendment 1: 31 May 2018', 'Amendment 1: Proposed List of Changes', 'The overall reason for the amendment: The overall reason for the amendment is to modify selected', 'Inclusion/Exclusion criteria due to difficulties regarding subject recruitment.', 'Text Changes', 'Description of change /', 'Applicable Section(s)', '(new text in bold/underlined, deleted text in', 'Rationale for Change', 'strikeout)', 'Throughout the document, minor typographical errors, misspellings and minor formatting issues have been', 'resolved. These minor changes are not listed in this summary.', 'Sponsor Approval', 'Diana Valencia, MD, Medical Affairs', 'B. Braun personnel and', 'contact information update.', 'Contact List', 'Angela Karpf Diana Valencia', 'B. Braun and Syneos', 'Corporate Vice Prosident Associate Director', 'personnel and contact', 'Telephone: +1 610-596-26422875', 'information updates.', 'Email:', 'agela.karpfdiana.valencia@bbraunusa.com', 'Christopher R. Curtin', 'Email: chris.curtin@bbraunusa.com', 'Sean D. Kennedy, MPH', 'Email: sean.kennedy@inventivhealth.com', 'sean.kennedy@syneoshealth.com', 'Synopsis: Study', 'At< 1 week 1 day after the screening', 'Clarification of duration', 'Design, Week 1', 'between Screening and', '(Baseline) Visit', 'Baseline visits.', 'Section 6.1:', 'Description of Overall', 'Study Design and', 'Plan', 'Section 9.2.1: Week 0', '(Screening)', 'Section 9.2.2: Week 1', '(Baseline)', '14 November 2018', 'Page 7']\n\n###\n\n", "completion": "END"}